Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy

This publication has 56 references indexed in Scilit:

• Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
  New England Journal of Medicine, 2008
• Frequent Engagement of the Classical and Alternative NF-κB Pathways by Diverse Genetic Abnormalities in Multiple Myeloma
  Cancer Cell, 2007
• Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion
  Leukemia, 2006
• Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials
  Leukemia, 2006
• Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study
  Blood, 2006
• International uniform response criteria for multiple myeloma
  Leukemia, 2006
• Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group
  Journal of Clinical Oncology, 2006
• Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
  New England Journal of Medicine, 2005
• Thalidomide for Patients With Relapsed Multiple Myeloma After High-Dose Chemotherapy and Stem Cell Transplantation: Results of an Open-Label Multicenter Phase 2 Study of Efficacy, Toxicity, and Biological Activity
  Mayo Clinic Proceedings, 2004
• CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
  British Journal of Haematology, 1998